English
Regional settings| Spread | 0.31 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 27.17 |
| Open | 27.13 |
| 1-Year Change | 2.53% |
| Day's Range | 27.13 - 27.78 |
Stevanato Group (STVN) is a multinational corporation specialising in systems, processes and services for the pharmaceutical, biotechnology and life sciences industries. Headquartered in Italy, the company offers its containment, delivery and diagnostic solutions in more than 70 countries. Its business operations are divided into two divisions: biopharmaceutical and diagnostic solutions; and engineering.
The company went public in July 2021, listing its shares on the New York Stock Exchange (NYSE) under the ticker symbol STVN.
Join Capital.com now to stay on top of the latest changes in the Stevanato Group stock price.
The Group’s first business, Nuova Ompi, was founded in 1949 as a producer of glass bottles, before moving into the manufacture of glass containers for use in the pharmaceutical industry. The Group expanded operations with the creation of SPAMI in 1971, which specialised in the manufacture of high-speed precision machines for the production of glass tube containers for pharmaceutical use. Over the years, Stevanato Group has made numerous acquisitions, including the purchase of glass manufacturing facility Alfamatic in 1993 and Slovakian glass manufacturer Medical Glass in 2005.
The biopharmaceutical and diagnostic solutions division focuses on the products, services and processes developed and provided for the containment and delivery of biotechnology and pharmaceutical drugs and reagents, as well as the production of diagnostic consumables.
The engineering division focuses on the equipment and technologies developed and provided to support the end-to-end biotechnology, pharmaceutical and diagnostic manufacturing processes, including assembly, visual inspection, packaging and serialisation, and glass converting.
As of July 2021, the company operated nine production plants for manufacturing and assembling pharmaceutical and healthcare products in Italy, Germany, Slovakia, Brazil, China, Mexico and the US; five plants for the machinery and equipment production in Italy and Denmark; two sites for analytical services in the US and Italy; and two commercial offices in the US and Japan.
Stevanato Group has more than 700 customers, including some of the world’s largest pharmaceutical, biotechnology and diagnostics companies, contract manufacturers and glass packaging producers.
With Capital.com’s comprehensive Stevanato Group stock chart, you can quickly view the company's current and historical performance.
On 21 June 2021, Stevanato Group filed an F-1 form with the US Securities and Exchange Commission (SEC) to go public on the NYSE. On 15 July, the company priced its initial public offering (IPO) at $21 a share. It raised $672m from the sale of 32 million shares, valuing the company at $6.3bn.
STVN stock debuted on 16 July, opening at $16.65 a share, 20.7% lower than the IPO price. The price then dropped to an intraday low of $16.61, before rising to close the first trading session at $19.67.
You can trace all the ups and downs of the Stevanato share price live and go long or short on the company’s shares with contracts for difference (CFDs) using Capital.com’s proprietary trading platform.
